Papers by Meletios Α. Dimopoulos
Page 8 · newest first
- Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsBritish Journal of Haematology · 2021
- Management of Patients with Difficult-To-Treat Multiple MyelomaFuture Oncology · 2021
- Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa StudyCancers · 2021
- Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD SettingCurrent Oncology · 2021
- Recovery of Innate Immune Cells and Persisting Alterations in Adaptive Immunity in the Peripheral Blood of Convalescent Plasma Donors at Eight Months Post SARS-CoV-2 InfectionMicroorganisms · 2021
- SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody ResponseVaccines · 2021
- Mutation-dependent treatment approaches for patients with complex multiple myelomaExpert Review of Precision Medicine and Drug Development · 2021
- Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or EverolimusFrontiers in Cardiovascular Medicine · 2021
- Trastuzumab Administration During Pregnancy: Un Update2021
- SARS-CoV-2 Vaccines in Patients With Multiple MyelomaHemaSphere · 2021
- Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.2021
- Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic ReviewCancers · 2021
- Clinical perspectives of BET inhibition in ovarian cancerCellular Oncology · 2021
- Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of AttenuationAmerican Journal of Roentgenology · 2021
- Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complicationsJournal of Biomedical Science · 2021
- How we treat endocrine complications of immune checkpoint inhibitorsESMO Open · 2021
- Daratumumab for Immunoglobulin Light Chain AmyloidosistouchREVIEWS in Oncology & Haematology · 2021
- Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosisTherapeutic Advances in Hematology · 2021
- Current and novel BTK inhibitors in Waldenström’s macroglobulinemiaTherapeutic Advances in Hematology · 2021
- Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 InfectionViruses · 2020
- A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myelomaBlood Advances · 2020
- Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trialBlood Advances · 2020
- Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to ChemotherapyCancers · 2020
- Supportive medication in cancer during pregnancyBMC Pregnancy and Childbirth · 2020
- Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative reviewAnnals of Translational Medicine · 2020
- Anti–SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical StudyMicroorganisms · 2020
- Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myelomaeJHaem · 2020
- Clinical Perspectives of ERCC1 in Bladder CancerInternational Journal of Molecular Sciences · 2020
- Analytical methodologies for the detection of SARS-CoV-2 in wastewater: Protocols and future perspectivesTrAC Trends in Analytical Chemistry · 2020
- A prognostic index predicting survival in transformed Waldenström macroglobulinemiaHaematologica · 2020
- Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myelomaBlood Advances · 2020
- Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM TrialBlood · 2020
- Consolidation Treatment with VRD Followed By Maintenance Therapy Versus Maintenance Alone in Newly Diagnosed, Transplant-Eligible Patients with Multiple Myeloma (MM): A Randomized Phase 3 Trial of the European Myeloma Network (EMN02/HO95)Blood · 2020
- Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup AnalysisBlood · 2020
- Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple MyelomaCancers · 2020
- The Addition of IMiDs for Patients with Daratumumab-Refractory Multiple Myeloma Can Overcome Refractoriness to Both AgentsBlood · 2020
- Derivation and Validation of a Predictive Score for Disease Worsening Inpatients with COVID-19Blood · 2020
- Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)Blood · 2020
- Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare StudyBlood · 2020
- Five-Year Follow-Up of Ibrutinib Plus Rituximab Vs Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase 3 iNNOVATETM StudyBlood · 2020
- Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXBlood Cancer Journal · 2020
- Efficacy and safety of weekly carfilzomib (70 mg/m²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studiesLeukemia & lymphoma/Leukemia and lymphoma · 2020
- Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myelomaBlood · 2020
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)Blood Cancer Journal · 2020
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 TrialJournal of Clinical Oncology · 2020
- Characterization of a PERK Kinase Inhibitor with Anti-Myeloma ActivityCancers · 2020
- Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based InductionJournal of Clinical Medicine · 2020
- Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic FactorsJAMA Oncology · 2020
- Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19Thrombosis and Haemostasis · 2020
- Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary ReportLife · 2020